Summary:
To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of schizophrenia
Qualified Participants Must:
• Be 18 years of age and older (Adult, Senior)
•
Have a clinical diagnosis of schizophrenia with a minimum duration of 1 year
Qualified Participants May Receive:
Study-related medical care and investigational medication at no cost and may be compensated for time and travel.